AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

Phase 2 Unknown 47 enrolled The First Affiliated Hospital of University of South China

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of AK104 plus concurrent chemoradiation therapy in unresectable locally advanced esophageal squamous cell carcinoma

Timeline

Start: 2022-10
Primary completion: 2023-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cadonilimab	Monoclonal antibody	10 mg/kg	—

AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications